Neil Woodford’s Latest €25M UK Biotech pay-out is to AMO Pharma

01/10/2015 - 2 minutes

As we already well know, Neil Woodford is an Economist investor listed as one of the most influential figures in the European biotech industry. From London (UK), his private equity firm Woodford Patient Capital Trust is now planning to dish out €25M to AMO Pharma, to further their phase II pipeline therapies for CNS disorders such as the super rare fragile X syndrome and myotonic dystrophy.

From past investments, it is clear Neil Woodford has a keen eye for up and coming biotech superstars, having recently invested over €800M in biotech companies such as PsiOxus, Oxford Science Innovation (alongside Google) and the Kymouse-platform from Kymab to name a couple.

It is therefore interesting to see what the likes of Neil Woodford see in the young AMO Pharma, founded in February.

Woodford investment

According to the FRAXA Research Foundation, fragile X syndrome is one of the most common causes of inherited autism and development of learning difficulties.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!